---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014848"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:28:21.173369+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Provectus appoints Pershing as CEO and Rodrigues as President effective April 16

## Summary
- Ed Pershing appointed CEO effective April 16; will continue as Board Chairman; salary $240,000/year.
- Dominic Rodrigues appointed President effective April 16; will continue as Vice Chairman; salary $240,000/year.
- Both executives have employment agreements with change-in-control severance provisions.
- Rodrigues' prior independent contractor agreement (March 2024) terminated; he had served as chief operating consultant.
- Press release outlines 2024 focus: pancreatic cancer clinical program, capital raising at fair valuation, and enhanced investor outreach.

## SEC filing metadata
- accession: 0001493152-24-014848
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014848
- JSON: https://secwatch.observer/filing/0001493152-24-014848.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014848.txt

## Key facts
- Executive change
  Dominic Rodrigues was appointed as President at PROVECTUS BIOPHARMACEUTICALS, INC..
  - Action: appointed
  - Role: President
  source text: appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm
- Executive change
  Ed Pershing was appointed as Chief Executive Officer at PROVECTUS BIOPHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.